Europe Cerebral Palsy Market

Europe Cerebral Palsy Market Size (2024 to 2029)

The cerebral palsy market size in Europe was valued at USD 1.04 billion in 2023. The European market size is expected to grow at a CAGR of 4.83% from 2024 to 2029 and be valued at USD 1.38 billion by 2029 from USD 1.09 billion in 2024.

The growing prevalence of cerebral palsy in Europe is driving the European market growth.

The growing patient population of cerebral palsy promoted the expansion of healthcare services and support systems for cerebral palsy to the needs of the patients. As per the data of the European Academy of Childhood Disability, more than 125,000 children and adults are currently suffering from cerebral palsy in Europe and the incidence of cerebral palsy can be seen in every 2 to 3 per 1000 live births. The growing prevalence of cerebral palsy is driving the demand for specialized medical care, rehabilitation services and support programs. The governments of European countries are taking initiatives to reduce the incidence of cerebral palsy, however, the need for comprehensive management and support for the existing the patient population is likely to drive the European cerebral palsy market growth.

Technological advancements in cerebral palsy treatment boost the European market expansion.

The recent innovations in medical technologies, especially in diagnostic imaging, such as MRI and CT scans have significantly improved the early detection and accurate diagnosis of cerebral palsy. That’s not all, the technological developments in the surgical techniques and minimally invasive procedures have further improved treatment outcomes. For instance, robotic-assisted therapies and neurorehabilitation technologies such as robotic exoskeletons are providing improved mobility and independence for cerebral palsy patients.

The rising awareness of cerebral palsy among the European population aids the European market growth.

The rise in the awareness of cerebral palsy among people and developments in diagnostic protocols resulted in the earlier and more accurate identification of cerebral palsy in Europe. Organizations such as Cerebral Palsy Europe (CPE) have played a significant role in boosting awareness about the signs and symptoms of CP among healthcare professionals and the public in Europe, and this has further resulted in a higher rate of early interventions that are crucial for improving long-term patient outcomes. This was also confirmed by one of the studies in the European Journal of Paediatrics. It was mentioned in the study that early diagnosis and intervention could notably reduce the severity of disability in children with cerebral palsy and continue highlighting the importance of spreading the awareness further.

In addition to the above, factors such as the support and funding from the governments of European countries to combat cerebral palsy, improvements in the rehabilitation services, increase in the number of specialized clinics and centres and growing number of R&D activities around cerebral palsy are boosting the European market growth.

High costs associated with the treatment and therapies of cerebral palsy are hindering the growth of the European market.

Furthermore, factors such as limited access to specialized care, the shortage of Trained Healthcare Professionals, the Variability in Healthcare Infrastructure Across Countries and Lack of Public and Private Insurance Coverage are hampering the European cerebral palsy market growth. Limited awareness and education about cerebral palsy, inconsistent policies and support for cerebral palsy from the governments of European countries, challenges in diagnosing mild cases, and slow adoption of advanced technologies in some countries of Europe are further inhibiting the growth rate of the European market.

KEY PLAYERS IN THE EUROPE CEREBRAL PALSY MARKET

Companies that play a notable role in the Europe cerebral palsy market include Abbott Laboratories (US), AbbVie Inc. (US), Acorda Therapeutics, Inc. (US), Allergan Plc (Ireland), AstraZeneca Plc (UK), Bayer AG (Germany), Biogen Inc. (US), Boston Scientific Corporation (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), GlaxoSmithKline Plc (UK), Ipsen (France), Johnson & Johnson (US), Medtronic Plc (Ireland), Merck & Co., Inc. (US), Merck KGaA (Germany), Novartis International AG (Switzerland), Pfizer Inc. (US), Roche Holding AG (Switzerland), Sanofi SA (France), Stryker Corporation (US) and Teva Pharmaceutical Industries Ltd. (Israel).

SEGMENTAL ANALYSIS

TYPE INSIGHTS

The spastic segment dominated the Europe cerebral palsy market in 2023 by type.

Spastic cerebral palsy is the most type of all. According to the statistics of CerebralPalsy.org, spastic accounts for 61% to 76.9% of all cerebral palsy cases. The growing prevalence of spastic cerebral palsy, perinatal complications and advancements in neonatal intensive care are driving the growth of the spastic segment in the European market. Factors such as improved therapeutic interventions and early intervention programs for spastic cerebral palsy are further bosting the segmental expansion in the European market. The European Academy of Childhood Disability says early diagnosis and early initiation of therapy can boost outcomes for children with spastic cerebral palsy.

TREATMENT INSIGHTS

The therapy segment led the cerebral palsy market in Europe in 2023.

Therapies such as physiotherapy, occupational therapy, and speech therapy are essential for cerebral palsy patients as these help them improve motor skills, communication abilities, and independence in cerebral palsy patients. In Europe, therapy sessions are considered as the major components in the multidisciplinary treatment plans that are designed for individual patient needs. As per the data of the European Academy of Childhood Disability, more than 80% of children suffering from cerebral palsy take regular physiotherapy to improve muscle strength and coordination in Europe.

MEDICAL DEVICES INSIGHTS

The orthotic devices segment accounted for the major share of the Europe cerebral palsy market in 2023.

Orthotic devices provide support in terms of stability and correction to affected limbs and body parts in cerebral palsy patients and helps improving the quality of life. Factors such as advancements in orthotic technology, growing awareness about non-invasive treatment options and rising preference from healthcare providers for conservative management approaches are propelling the growth of the orthotic devices segment in the Europe cerebral palsy market. For instance, as per the data from the European Journal of Physical and Rehabilitation Medicine, more than 70% of children with cerebral palsy leverage orthotic devices to improve their mobility.

END-USER INSIGHTS

The physiotherapy centers segment accounted for the leading share of the European market in 2023.

Physiotherapy centers provide specialized rehabilitation services that focus on improving motor functions and mobility to cerebral palsy patients. The growing awareness about the effectiveness of physical therapy in improving the quality of life for cerebral palsy patients is majorly propelling the expansion of the physiotherapy centers segment in the global market. According to the statistics of the Journal of Pediatric Rehabilitation Medicine, physiotherapy interventions are believed to reduce the severity of cerebral palsy symptoms by up to 30% in pediatric patients.

REGIONAL ANALYSIS

The UK held the leading share of the European market in 2023.

The UK holds a prominent position in the Europe cerebral palsy market. The growing prevalence of cerebral palsy in the UK is propelling the UK market growth. As per the National Institute for Health and Care Excellence, the prevalence of cerebral palsy in the UK is 2 to 3 per 1000 live births. The presence of advanced healthcare infrastructure and comprehensive support systems for neurological disorders are majorly driving the cerebral palsy market in the UK. The government of the UK supports neurological care and rehabilitation services, which is boosting the UK market growth. The advanced research initiatives in the UK with a focus on neurorehabilitation and innovative therapies for cerebral palsy management are a big plus to the growth rate of the UK market.

DETAILED SEGMENTATION OF THE EUROPE CEREBRAL PALSY MARKET INCLUDED IN THIS REPORT

This research report on the Europe cerebral palsy market has been segmented and sub-segmented based on the following categories.

By Type

• Ataxia
• Spastic
• Dyskinetic
• Athetoid
• Postnatal
• Congenital
• Hemiparesis
• Hypotonic
• Diplegia

By Treatments

• Surgery
• Medication
• Therapy
• Diagnosis
• Laboratory Tests
• Imaging Tests
• Others

By Medical Devices

• Orthotic Devices
• ENT Devices
• Eye-tracking Devices

By End-users

• Physiotherapy Centers
• Hospitals
• Specialty Clinics
• Home Care
• Pathology Centers
• Ambulatory
• Others

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic